105 related articles for article (PubMed ID: 23353843)
41. Influence of combined therapy with rosuvastatin and amitriptyline on the oxidation-reduction status in rats.
Herbet M; Gawrońska-Grzywacz M; Graca A; Jagiełło-Wójtowicz E
Acta Pol Pharm; 2013; 70(5):913-7. PubMed ID: 24147371
[TBL] [Abstract][Full Text] [Related]
42. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet.
Famer D; Crisby M
Neurosci Lett; 2007 May; 419(1):68-73. PubMed ID: 17433542
[TBL] [Abstract][Full Text] [Related]
43. Cardioprotective effects of low-dose combination therapy with rosuvastatin and fasudil in the isolated rat heart.
Wu N; Li W; Lv Y; Shu W; Jia D
Pharmazie; 2014 Sep; 69(9):704-8. PubMed ID: 25272944
[TBL] [Abstract][Full Text] [Related]
44. [A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats].
Sicard P; Lauzier B; Oudot A; Busseuil D; Collin B; Duvillard L; Moreau D; Vergely C; Rochette L
Arch Mal Coeur Vaiss; 2005; 98(7-8):804-8. PubMed ID: 16220751
[TBL] [Abstract][Full Text] [Related]
45. Rapid response to lipids profile and leukocyte gene expression after rosuvastatin administration in Chinese healthy volunteers.
Hua CX; Li YS; Liu YQ; Liu H; Li N; Wu Y; Xu L; Huang YL
Chin Med J (Engl); 2008 Jul; 121(13):1215-9. PubMed ID: 18710642
[TBL] [Abstract][Full Text] [Related]
46. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
Ho RH; Tirona RG; Leake BF; Glaeser H; Lee W; Lemke CJ; Wang Y; Kim RB
Gastroenterology; 2006 May; 130(6):1793-806. PubMed ID: 16697742
[TBL] [Abstract][Full Text] [Related]
47. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes.
Laumen H; Skurk T; Hauner H
Atherosclerosis; 2008 Feb; 196(2):565-73. PubMed ID: 17692320
[TBL] [Abstract][Full Text] [Related]
48. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin.
White CM
J Clin Pharmacol; 2002 Sep; 42(9):963-70. PubMed ID: 12211221
[TBL] [Abstract][Full Text] [Related]
49. Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects.
Jindal D; Tandon M; Sharma S; Pillai KK
Eur J Clin Pharmacol; 2005 Oct; 61(9):621-5. PubMed ID: 16133549
[TBL] [Abstract][Full Text] [Related]
50. Effect of rosuvastatin treatment on cholesterol efflux from human macrophages.
Kralova Lesna I; Adamkova V; Pagacova L
Neuro Endocrinol Lett; 2011; 32 Suppl 2():24-8. PubMed ID: 22101878
[TBL] [Abstract][Full Text] [Related]
51. Effects of HMG-CoA reductase inhibitor on experimental autoimmune myocarditis.
Liu X; Li B; Wang W; Zhang C; Zhang M; Zhang Y; Xia Y; Dong Z; Guo Y; An F
Cardiovasc Drugs Ther; 2012 Apr; 26(2):121-30. PubMed ID: 22382902
[TBL] [Abstract][Full Text] [Related]
52. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy.
Chang SA; Kim YJ; Lee HW; Kim DH; Kim HK; Chang HJ; Sohn DW; Oh BH; Park YB
Hypertension; 2009 Sep; 54(3):591-7. PubMed ID: 19564547
[TBL] [Abstract][Full Text] [Related]
53. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
54. Beneficial effects of rosuvastatin on aortic adverse remodeling in nitric oxide-deficient rats.
Neto-Ferreira R; Novaes Rocha V; da Silva Torres T; Mandarim-de-Lacerda CA; de Carvalho JJ
Exp Toxicol Pathol; 2011 Jul; 63(5):473-8. PubMed ID: 20537513
[TBL] [Abstract][Full Text] [Related]
55. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin.
Ajith TA; Riji T; Anu V
Clin Exp Pharmacol Physiol; 2008 May; 35(5-6):625-9. PubMed ID: 18177480
[TBL] [Abstract][Full Text] [Related]
56. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosenson RS
Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
[TBL] [Abstract][Full Text] [Related]
57. Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat.
van der Harst P; Groenewegen HC; Roks AJ; Buikema H; Zijlstra F; van Gilst WH; de Smet BJ
Coron Artery Dis; 2008 Feb; 19(1):47-53. PubMed ID: 18281816
[TBL] [Abstract][Full Text] [Related]
58. Erythrocyte membrane cholesterol and lipid core growth in a rabbit model of atherosclerosis: modulatory effects of rosuvastatin.
Tziakas D; Chalikias G; Kapelouzou A; Tentes I; Schäfer K; Karayannakos P; Kostakis A; Boudoulas H; Konstantinides S
Int J Cardiol; 2013 Dec; 170(2):173-81. PubMed ID: 24215985
[TBL] [Abstract][Full Text] [Related]
59. The methyl ester of rosuvastatin elicited an endothelium-independent and 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent relaxant effect in rat aorta.
López-Canales JS; López-Sanchez P; Perez-Alvarez VM; Wens-Flores I; Polanco AC; Castillo-Henkel E; Castillo-Henkel C
Braz J Med Biol Res; 2011 May; 44(5):438-44. PubMed ID: 21445535
[TBL] [Abstract][Full Text] [Related]
60. Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats.
Mooradian AD; Haas MJ
Am J Ther; 2007; 14(1):41-5. PubMed ID: 17303974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
